{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:18:11Z","timestamp":1783491491329,"version":"3.55.0"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic malignancies, yet its efficacy in solid tumors and durability across broader application remain limited. A central challenge lies in how CAR signaling is initiated, amplified, and regulated over time. Unlike the native T cell receptor (TCR), CARs are synthetic, modular receptors whose signaling output is dictated by the composition and spatial organization of their extracellular, transmembrane, and intracellular domains. Emerging evidence suggests that CAR signaling requirements are not static: insufficient signaling at early time points can impair activation and tumor clearance, whereas excessive or prolonged signaling promotes exhaustion, toxicity, and loss of persistence. More recent CAR designs therefore emphasize fine-tuned signaling, embracing a \u201cless-is-more\u201d paradigm to balance potency with durability. In this review, we summarized recent advances in CAR signaling biology, focusing on temporal signaling thresholds, modular design principles, and emerging strategies to precisely control signal strength and quality. Finally, we discuss how high-throughput screening, computational modeling, and machine learning approaches may enable disease-specific, personalized CAR designs in the future.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1893076","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:05Z","timestamp":1783490045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors"],"prefix":"10.3389","volume":"17","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medicine, Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjia","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gradishar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]},{"name":"Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]},{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]},{"name":"Biohub","place":["Chicago, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]},{"name":"Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]},{"name":"Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"Car t cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car t-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified t cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of cd19 car therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following car t cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to car t cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"Car t cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (zuma-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/annonc\/mdq325","article-title":"Cancer-testis antigen expression in triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2011","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.10.007","article-title":"Exploiting t cell signaling to optimize engineered t cell therapies","volume":"8","author":"Wang","year":"2022","journal-title":"Trends Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from t cell receptors (tcrs) and chimeric antigen receptors (cars) on t cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF00820666","article-title":"The t-body approach: potential for cancer immunotherapy","volume":"18","author":"Eshhar","year":"1996","journal-title":"Springer Semin Immunopathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.15.1464371","article-title":"Endowing t cells with antibody specificity using chimeric t cell receptors","volume":"6","author":"Gross","year":"1992","journal-title":"FASEB J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through t cell receptor-zeta chain alone are insufficient to prime resting t lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.v96.5.1999.h8001999_1999_2001","article-title":"Chimeric fv-zeta or fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral t cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1bb costimulation ameliorates t cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of t cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and t-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive t cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-065X.2009.00843.x","article-title":"Organization of proximal signal initiation at the tcr:cd3 complex","volume":"232","author":"Guy","year":"2009","journal-title":"Immunol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri3403","article-title":"T cell receptor signalling networks: branched, diversified and bounded","volume":"13","author":"Brownlie","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor t cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/356607a0","article-title":"Cd28-mediated signalling co-stimulates murine t cells and prevents induction of anergy in t-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent cd28 signaling selectively enhances survival and proliferation in genetically modified activated human primary t lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific t cell activation by recombinant immunoreceptors: cd3 zeta signaling and cd28 costimulation are simultaneously required for efficient il-2 secretion and can be integrated into one combined cd28\/cd3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary t cells with chimeric receptors: costimulation from cd28, inducible costimulator, cd134, and cd137 in series with signals from the tcr zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in car t cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing car t cell persistence through icos and 4-1bb costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1bb and cd28 signaling domains augment pi3kinase\/akt\/bcl-xl activation and cd8+ t cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human t cells containing cd28 and cd137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.192","article-title":"Arming cytokine-induced killer cells with chimeric antigen receptors: cd28 outperforms combined cd28-ox40 \"super-stimulation","volume":"21","author":"Hombach","year":"2013","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation cd19-specific car-t cells in b cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.11.007","article-title":"Il-36gamma armored car t cells reprogram neutrophils to induce endogenous antitumor immunity","volume":"44","author":"Zuo","year":"2025","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618404","article-title":"Il-7 armed binary car t cell strategy to augment potency against solid tumors","volume":"16","author":"Torres Chavez","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"Ccr5 and il-12 co-expression in car t cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured gpc3 car t cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01509-2","article-title":"Solid tumour car-t cells engineered with fusion proteins targeting pd-l1 for localized il-12 delivery","volume":"10","author":"Murad","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1498706","article-title":"Co-expression of il-15\/il-15ra complex enhances nkg2d-car t cell-mediated anti-pancreatic cancer immunity by activating the jak\/stat5 signaling pathway","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0226","article-title":"Therapeutic efficacy of il7\/ccl19-expressing car-t cells in intractable solid tumor models of glioblastoma and pancreatic cancer","volume":"4","author":"Ohta","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","article-title":"Il-18-secreting car t cells targeting dll3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine il-2 and il-33 armored car t cells reshape the tumor microenvironment and reduce growth of multiple solid tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4795171","article-title":"Engineered il-7 receptor enhances the therapeutic effect of axl-car-t cells on triple-negative breast cancer","volume":"2020","author":"Zhao","year":"2020","journal-title":"BioMed Res Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of il7 and ccl21 increases efficacy of car-t cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific car t cells coexpressing il15 and il21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered t cells using orthogonal il-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"Il-7 and ccl19 expression in car-t cells improves immune cell infiltration and car-t cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse car t cells secreting il-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"Car t cells releasing il-18 convert to t-bet(high) foxo1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","article-title":"Il-12 secreting tumor-targeted chimeric antigen receptor t cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"Il-12 release by engineered t cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241398","article-title":"Il-7 and il-21 are superior to il-2 and il-15 in promoting human t cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 engineering improves car t cell function in solid tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02019","article-title":"Phase i trial of gd2.cart cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric cns tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced car t-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase i clinical trial of autologous chimeric antigen receptor (car) t cells genetically engineered to secrete il-12 and to target the muc16ecto antigen in patients (pts) with muc16ecto+ recurrent high-grade serous ovarian cancer (hgsoc)","volume":"159","author":"O'Cearbhaill","year":"2020","journal-title":"Gynecologic Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in car t cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020375","article-title":"Design and characterization of an \"all-in-one\" lentiviral vector system combining constitutive anti-g(d2) car expression and inducible cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02060-8","article-title":"Il-10-expressing car t cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0347-5","article-title":"Car t cell therapy for breast cancer: harnessing the tumor milieu to drive t cell activation","volume":"6","author":"Bajgain","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01691","article-title":"An il-4\/21 inverted cytokine receptor improving car-t cell potency in immunosuppressive solid-tumor microenvironment","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing psma-car-t cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative tgf-beta receptor enhances psma-targeted human car t cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"Psma-targeting tgfbeta-insensitive armored car t cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae126","article-title":"Il-13ralpha2\/tgf-beta bispecific car-t cells counter tgf-beta-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific t-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","article-title":"Engineered cxcr3-a expression enhances b7-h3-targeting car t cell migration and efficacy against diffuse intrinsic pontine glioma","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-1920","article-title":"Cxcr3 enhanced murine chimeric antigen receptor t cells in the treatment of solid tumors","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-25-0149","article-title":"Tunneling cars: increasing car t-cell tumor infiltration through the overexpression of mmp-7 and osteopontin-b","volume":"13","author":"Van Pelt","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0876","article-title":"Secretion of a vegf-blocking scfv enhances car t-cell potency","volume":"13","author":"Supper","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01056-4","article-title":"Engineering t cells with a membrane-tethered version of slp-76 overcomes antigen-low resistance to car t cell therapy","volume":"6","author":"Rotiroti","year":"2025","journal-title":"Nat Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-02031-x","article-title":"Idr-induced car condensation improves the cytotoxicity of car-ts against low-antigen cancers","volume":"22","author":"Zhang","year":"2025","journal-title":"Nat Chem Biol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.11.005","article-title":"Ptalpha enhances mrna translation and potentiates car t cells for solid tumor eradication","volume":"189","author":"Shi","year":"2025","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01621-1","article-title":"Hla-independent t cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive car t cells redefine targetable cd70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of gd2 chimeric antigen receptor t cells by expression of the chemokine receptor ccr2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional ccr2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.628906","article-title":"Chemokine receptor ccr2b enhanced anti-tumor function of chimeric antigen receptor t cells targeting mesothelin in a non-small-cell lung carcinoma model","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"Cxcr1- or cxcr2-modified car t cells co-opt il-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050674","article-title":"Car t-cells targeting the integrin alphavbeta6 and co-expressing the chemokine receptor cxcr2 demonstrate enhanced homing and efficacy against several solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2021-153871","article-title":"A bcl2l1 armoured bcma targeting car t cell to overcome exhaustion and enhance persistence in multiple myeloma","volume":"138","author":"Maity","year":"2021","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active myd88\/cd40 costimulation enhances expansion and efficacy of chimeric antigen receptor t cells targeting hematological Malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030745","article-title":"A pooled primate screen finds that myd88-cd40 boosts car-t","volume":"146","author":"Leick","year":"2025","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0263","article-title":"Inducible activation of myd88 and cd40 in car t cells results in controllable and potent antitumor activity in preclinical solid tumor models","volume":"7","author":"Mata","year":"2017","journal-title":"Cancer Discov"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136093","article-title":"Myd88\/cd40 signaling retains car t cells in a less differentiated state","volume":"5","author":"Prinzing","year":"2020","journal-title":"JCI Insight"},{"key":"B90","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","article-title":"Efficacy and safety of third-generation cd19-car t cells incorporating cd28 and tlr2 intracellular domains for b-cell Malignancies with central nervous system involvement: results of a pivotal trial","volume":"23","author":"He","year":"2025","journal-title":"J Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of car-redirected t lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving car-t immunotherapy: overcoming the challenges of t cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109078","article-title":"Stem cell like memory t cells: a new paradigm in cancer immunotherapy","volume":"241","author":"Wang","year":"2022","journal-title":"Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and car-t cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced car t cell expansion and prolonged persistence in pediatric patients with all treated with a low-affinity cd19 car","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01585-2","article-title":"Low-affinity car t cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing car t cell expansion","volume":"36","author":"Olson","year":"2022","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","article-title":"Affinity fine-tuning anti-caix car-t cells mitigate on-target off-tumor side effects","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00803-5","article-title":"Positively charged patches: tonic for car fitness","volume":"33","author":"Khan","year":"2023","journal-title":"Cell Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a car to the trac locus with crispr\/cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.007","article-title":"Promoter usage regulating the surface density of car molecules may modulate the kinetics of car-t cells in vivo","volume":"21","author":"Ho","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo0514","article-title":"Car density influences antitumoral efficacy of bcma car t cells and correlates with clinical outcome","volume":"8","author":"Rodriguez-Marquez","year":"2022","journal-title":"Sci Adv"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724211","article-title":"Reducing hinge flexibility of car-t cells prolongs survival in vivo with low cytokines release","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-cd19 car t cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.26586","article-title":"A novel adoptive synthetic tcr and antigen receptor (star) t-cell therapy for b-cell acute lymphoblastic leukemia","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5191","article-title":"Chimeric star receptors using tcr machinery mediate robust responses against solid tumors","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.02.001","article-title":"Converting tcr-based chimeric antigen receptor star into dual-specific targeting receptor for cancer immunotherapy","volume":"33","author":"Yu","year":"2025","journal-title":"Mol Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of car activation potential directs alternative t cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509980","article-title":"The impact of cd3zeta itam multiplicity and sequence on car t-cell survival and function","volume":"15","author":"Majumdar","year":"2024","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02424","article-title":"Results from first-in-human phase i study of a novel cd19-1xx chimeric antigen receptor with calibrated signaling in large b-cell lymphoma","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2024-209964","article-title":"Enhancing car t cell efficacy by modulating pi3k signaling via a synthetic cd28 rheostat","volume":"144","author":"Shahid","year":"2024","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adz0529","article-title":"Zap327 signaling domain-driven chimeric antigen receptor generates robust and long-term antitumor immunity in mouse models","volume":"17","author":"Liu","year":"2025","journal-title":"Sci Transl Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"C-jun overexpression in car t cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623869","article-title":"Reshaping car-t cells through overexpression of t cell factor 1","volume":"16","author":"Yao","year":"2025","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010962","article-title":"T-bet overexpression enhances car t cell effector functions and antigen sensitivity","volume":"13","author":"Cimons","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1319","article-title":"Disruption of suv39h1-mediated h3k9 methylation sustains car t-cell function","volume":"14","author":"Jain","year":"2024","journal-title":"Cancer Discov"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1350","article-title":"Suv39h1 ablation enhances long-term car t function in solid tumors","volume":"14","author":"Lopez-Cobo","year":"2024","journal-title":"Cancer Discov"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted car-t cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0351","article-title":"351 vitamin c treatment prevents car t cell exhaustion, maintains stem cell phenotype and enhances antitumor function","volume":"10","author":"Kouakanou","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02856-w","article-title":"Integrated epigenetic and genetic programming of primary human t cells","author":"Goudy","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","article-title":"Glut1 overexpression in car-t cells induces metabolic reprogramming and enhances potency","volume":"15","author":"Guerrero","year":"2024","journal-title":"Nat Commun"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.033","article-title":"Gsnor overexpression enhances car-t cell stemness and anti-tumor function by enforcing mitochondrial fitness","volume":"32","author":"Niu","year":"2024","journal-title":"Mol Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic t cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9209","article-title":"Engineering light-controllable car t cells for cancer immunotherapy","volume":"6","author":"Huang","year":"2020","journal-title":"Sci Adv"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00982-5","article-title":"Nano-optogenetic engineering of car t cells for precision immunotherapy with enhanced safety","volume":"16","author":"Nguyen","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.02.035","article-title":"Engineering sonogenetic echoback-car t cells","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of car-t cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for car t cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor t-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated car-t cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01571-5","article-title":"Ctla-4 tail fusion enhances car-t antitumor immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by t cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","article-title":"Synnotch car circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"Synnotch-car t cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.03.023","article-title":"Modular design of synthetic receptors for programmed gene regulation in cell therapies","volume":"185","author":"Zhu","year":"2022","journal-title":"Cell"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0945","article-title":"Tuning the antigen density requirement for car t-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in car-t cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581210","article-title":"Mathematical models and computational approaches in car-t therapeutics","volume":"16","author":"Putignano","year":"2025","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105597","article-title":"Computational modelling of car t-cell therapy: From cellular kinetics to patient-level predictions","volume":"113","author":"Murias-Closas","year":"2025","journal-title":"EBioMedicine"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0240","article-title":"Advancing car t-cell therapies with artificial intelligence: Opportunities and challenges","volume":"6","author":"Luciani","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-00936-1","article-title":"Car-toner: An ai-driven approach for car tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68272-5","article-title":"Ai-guided car designs and targeted pathway modulation to enhance multi-antigen car t cell durability and overcome antigen escape","volume":"17","author":"Ansari","year":"2026","journal-title":"Nat Commun"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2026.03.03.709355","DOI":"10.64898\/2026.03.03.709355","article-title":"Validation and analysis of 12,000 ai-driven car-t designs in the bits to binders competition","author":"Kosonocky","year":"2026","journal-title":"bioRxiv"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70107","article-title":"Comic: A bayesian dose optimization design for drug combination in multiple indications with application to car\u2010t therapies","volume":"44","author":"Chen","year":"2025","journal-title":"Stat Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2024.12.16.628628","DOI":"10.1101\/2024.12.16.628628","article-title":"Quantification of car t cell performance against acute myeloid leukemia using bayesian inference","author":"Shah","year":"2024","journal-title":"bioRxiv"},{"key":"B146","doi-asserted-by":"publisher","first-page":"218257","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable smart car-t design: A new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","volume":"640","author":"Wen","year":"2026","journal-title":"Cancer Lett"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of car and non-car t cells within the tumor microenvironment following car t cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of car-t cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering car-t cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m700976200","article-title":"Different t cell receptor affinity thresholds and cd8 coreceptor dependence govern cytotoxic t lymphocyte activation and tetramer binding properties","volume":"282","author":"Laugel","year":"2007","journal-title":"J Biol Chem"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.9.4493","article-title":"Interplay between Tcr affinity and necessity of coreceptor ligation: High-affinity peptide-Mhc\/Tcr interaction overcomes lack of Cd8 engagement","volume":"171","author":"Kerry","year":"2003","journal-title":"J Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","article-title":"Tcr signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion","volume":"219","author":"Shakiba","year":"2021","journal-title":"J Exp Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1562248","article-title":"Deciphering the deterministic role of Tcr signaling in T cell fate determination","volume":"16","author":"Qin","year":"2025","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1063\/5.0073746","article-title":"Engineering Car T cells for enhanced efficacy and safety","volume":"6","author":"Wu","year":"2022","journal-title":"APL Bioeng"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti\u2013Cd20-Cd28-Cd3 Z chimeric antigen receptor\u2013modified effector Cd8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-022-00896-0","article-title":"Screening for Cd19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains","volume":"6","author":"Gordon","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0225","article-title":"Decoding Car T cell phenotype using combinatorial signaling motif libraries and machine learning","volume":"378","author":"Daniels","year":"2022","journal-title":"Science"},{"key":"B159","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1101\/2021.08.23.457342","article-title":"Speedingcars: Accelerating the engineering of Car T cells by signaling domain shuffling and single-cell sequencing","volume":"13","author":"Castellanos-Rueda","year":"2022","journal-title":"Nat Commun"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2025.101260","article-title":"Library-based single-cell analysis of Car signaling reveals drivers of in vivo persistence","volume":"16","author":"Perez","year":"2025","journal-title":"Cell Syst"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.008","article-title":"Refining chimeric antigen receptors via barcoded protein domain combination pooled screening","volume":"31","author":"Rios","year":"2023","journal-title":"Mol Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp4008","article-title":"Dissecting the role of Car signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing","volume":"11","author":"Castellanos-Rueda","year":"2025","journal-title":"Sci Adv"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of Car T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci Transl Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1786582","article-title":"Integrative single-cell multi-omics of Cd19-Carpos and Carneg T cells suggest drivers of immunotherapy response in B cell neoplasias","volume":"5","author":"Guerrero-Murillo","year":"2024","journal-title":"Cell Rep Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12859-026-06401-7","article-title":"Enhancing Car-T cell activity prediction via fine-tuning protein language models with generated Car sequences","volume":"27","author":"Yoshida","year":"2026","journal-title":"BMC Bioinf"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1635159","article-title":"Smart Car-T nanosymbionts: Archetypes and proto-models","volume":"16","author":"Baena","year":"2025","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70124","article-title":"Strategies of Ai\u2010driven Car\u2010T cell therapy towards solid tumours","volume":"178","author":"Abdalla","year":"2026","journal-title":"Immunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:07Z","timestamp":1783490047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1893076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":167,"alternative-id":["10.3389\/fimmu.2026.1893076"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1893076","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1893076"}}